Pirozzi, Gianluca
Sanofi (United States)
7 papers on CoChatORCID 0000-0001-5073-4916
Most cited papers
- Verified
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine
Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis
Cited by 2,110
- Verified
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial
Bachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA
Sinusitis and nasal conditionsCystic Fibrosis Research Advances
Cited by 794
- Verified
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery
Asthma and respiratory diseasesIL-33, ST2, and ILC Pathways
Cited by 766
- Verified
Commonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology
Dermatology and Skin DiseasesAsthma and respiratory diseases
Cited by 493
- Verified
Conjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology
Dermatology and Skin DiseasesOcular Surface and Contact Lens
Cited by 442
- Verified
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Deleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology
Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis
Cited by 255
- Verified
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Hamilton, J. D., Harel, S., Swanson, B. N., Brian, W., Chen, Z., Rice, M. S., Amin, N., Ardeleanu, M., Radin, A., Shumel, B., et al. (2021) · Clinical & Experimental Allergy
Dermatology and Skin DiseasesAsthma and respiratory diseases
Cited by 192
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free